JP2015523330A5 - - Google Patents

Download PDF

Info

Publication number
JP2015523330A5
JP2015523330A5 JP2015511734A JP2015511734A JP2015523330A5 JP 2015523330 A5 JP2015523330 A5 JP 2015523330A5 JP 2015511734 A JP2015511734 A JP 2015511734A JP 2015511734 A JP2015511734 A JP 2015511734A JP 2015523330 A5 JP2015523330 A5 JP 2015523330A5
Authority
JP
Japan
Prior art keywords
composition
composition according
pharmaceutical composition
bacterial biofilm
ulcer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015511734A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523330A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/040514 external-priority patent/WO2013170128A1/en
Publication of JP2015523330A publication Critical patent/JP2015523330A/ja
Publication of JP2015523330A5 publication Critical patent/JP2015523330A5/ja
Withdrawn legal-status Critical Current

Links

JP2015511734A 2012-05-11 2013-05-10 細菌性バイオフィルムを除去するためのセアプローゼの使用 Withdrawn JP2015523330A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261645815P 2012-05-11 2012-05-11
US61/645,815 2012-05-11
US201361820915P 2013-05-08 2013-05-08
US61/820,915 2013-05-08
PCT/US2013/040514 WO2013170128A1 (en) 2012-05-11 2013-05-10 Use of seaprose to remove bacterial biofilm

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018003062A Division JP2018083830A (ja) 2012-05-11 2018-01-12 細菌性バイオフィルムを除去するためのセアプローゼの使用

Publications (2)

Publication Number Publication Date
JP2015523330A JP2015523330A (ja) 2015-08-13
JP2015523330A5 true JP2015523330A5 (cg-RX-API-DMAC7.html) 2016-06-30

Family

ID=48468851

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015511734A Withdrawn JP2015523330A (ja) 2012-05-11 2013-05-10 細菌性バイオフィルムを除去するためのセアプローゼの使用
JP2018003062A Pending JP2018083830A (ja) 2012-05-11 2018-01-12 細菌性バイオフィルムを除去するためのセアプローゼの使用
JP2019050562A Active JP7118022B2 (ja) 2012-05-11 2019-03-19 細菌性バイオフィルムを除去するためのセアプローゼの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018003062A Pending JP2018083830A (ja) 2012-05-11 2018-01-12 細菌性バイオフィルムを除去するためのセアプローゼの使用
JP2019050562A Active JP7118022B2 (ja) 2012-05-11 2019-03-19 細菌性バイオフィルムを除去するためのセアプローゼの使用

Country Status (16)

Country Link
US (1) US11096992B2 (cg-RX-API-DMAC7.html)
EP (1) EP2849777B1 (cg-RX-API-DMAC7.html)
JP (3) JP2015523330A (cg-RX-API-DMAC7.html)
KR (1) KR20150013280A (cg-RX-API-DMAC7.html)
CN (1) CN104602700A (cg-RX-API-DMAC7.html)
AU (1) AU2013259360B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014027995A2 (cg-RX-API-DMAC7.html)
CA (1) CA2872530A1 (cg-RX-API-DMAC7.html)
CL (1) CL2014003059A1 (cg-RX-API-DMAC7.html)
CO (1) CO7250444A2 (cg-RX-API-DMAC7.html)
IL (1) IL235617A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN09412A (cg-RX-API-DMAC7.html)
MX (1) MX2014013745A (cg-RX-API-DMAC7.html)
NZ (1) NZ701623A (cg-RX-API-DMAC7.html)
RU (1) RU2014145270A (cg-RX-API-DMAC7.html)
WO (1) WO2013170128A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
KR20150013280A (ko) 2012-05-11 2015-02-04 스미스 앤드 네퓨, 인크. 박테리아 균막을 제거하기 위한 세아프로제의 용도
CN109260465A (zh) 2012-11-14 2019-01-25 史密夫和内修公司 稳定的嗜热菌蛋白酶水凝胶
CN105050629B (zh) 2013-03-15 2018-09-25 史密夫和内修公司 用于递送活性剂的可溶解的形成凝胶的膜
EP2857025A1 (en) * 2013-10-02 2015-04-08 Special Water Patents B.V. Wound treatment composition
EP3120866A1 (en) 2015-07-24 2017-01-25 Zymetech ehf. Use of marine serine proteases for removal, prevention and inhibition of formation and growth of biofilms
WO2018020435A1 (en) * 2016-07-27 2018-02-01 Smith & Nephew, Inc. Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces
WO2018071506A1 (en) * 2016-10-11 2018-04-19 Sharklet Technologies, Inc Composition for biofilm disruption, methods of manufacture thereof and articles comprising the same
US11413300B2 (en) 2017-01-30 2022-08-16 Smith & Nephew, Inc. Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces
US20200289552A1 (en) * 2017-07-04 2020-09-17 Fluchem Ltd Solid composition comprising iodine agent and sodium chloride having improved water solubility, and antiviral and antimicrobial composition for eye, oral cavity, nasal cavity or inhalation containing aqueous solution thereof
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP4189051B1 (en) * 2020-07-27 2024-02-28 Unilever IP Holdings B.V. Use of an enzyme and surfactant for inhibiting microorganisms

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197291A (en) 1974-01-08 1980-04-08 Gerold K. V. Klein Hydrolytic enzyme material
JPS5692217A (en) 1979-12-26 1981-07-25 Kowa Co Easily absorbable enzyme preparation
IT1264322B (it) 1992-07-30 1996-09-23 Lanfranco Callegaro Esteri di gellano autoreticolato, procedimento di preparazione e loro applicazioni farmaceutiche e biomedico-sanitarie
CA2106609A1 (en) 1992-09-28 1994-03-29 Irene Yeatman Aldridge Proteases to inhibit and remove biofilm
US5902600A (en) 1992-12-21 1999-05-11 Healthpoint, Ltd. Hydrogel polymer wound dressing
US6395529B1 (en) 1998-11-10 2002-05-28 Novozymes Biotech, Inc. Polypeptides having lactonohydrolase activity and nucleic acids encoding same
US6399092B1 (en) 2000-12-27 2002-06-04 Healthpoint, Ltd. Anhydrous, hydrophilic absorbent wound dressing (tube) with antimicrobials or other pharmaceutically active agents
US6548556B2 (en) 2000-12-27 2003-04-15 Healthpoint, Ltd. Stable enzymatic wound debrider
US20030026794A1 (en) * 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
US6479060B1 (en) 2001-09-04 2002-11-12 Healthpoint, Ltd. Elegant hydrogenated castor oil ointments
US20030198631A1 (en) 2002-04-18 2003-10-23 Healthpoint, Ltd. Thermolysin enzymatic wound debrider
CA2501645A1 (en) 2002-10-10 2004-04-22 Verenium Corporation Proteases, nucleic acids encoding them and methods for making and using them
US20050079594A1 (en) 2002-10-31 2005-04-14 Karine Marion Method of removing a biofilm
NZ555378A (en) 2002-12-20 2008-10-31 Univ New Jersey Med Compositions and methods for enzymatic detachment of bacterial and fungal biofilms
US8821862B2 (en) 2002-12-20 2014-09-02 Kane Biotech Inc. Soluble β-N-acetylglucosaminidase based antibiofilm compositions and uses thereof
US20100221237A1 (en) 2003-03-26 2010-09-02 Biosynexus Incorporated Enzyme disruption of bacterial biofilms
US7785584B2 (en) 2003-08-13 2010-08-31 Healthpoint, Ltd. Ointment wound spray
ES2421538T3 (es) * 2003-10-29 2013-09-03 Cystic Fibrosis Foundation Therapeutics Inc Proteasas no pancreáticas para controlar la concentración de colecistocinina (CCK) en plasma y para tratar el dolor
GB0326194D0 (en) 2003-11-10 2003-12-17 Univ Kent Canterbury Proteins involved in signal transduction
JP2007537200A (ja) 2004-05-14 2007-12-20 ハンス−ディートリヒ・ポラシェグ タウロリジン製剤及び投与:細菌マイクロフィルム形成に対する治療処置及び抗菌保護
EP1666075A1 (en) 2004-10-04 2006-06-07 Switch Biotech Aktiengesellschaft Wound dressing compositions, especially for delivery of protease inhibitors
IL165334A0 (en) 2004-11-22 2006-01-15 Mediwound Ltd Debriding composition from bromelain and methods of producing same
EP1942930A2 (en) * 2005-10-11 2008-07-16 Amano Enzyme USA., Ltd. Enzyme inhibitors of pai-1
US8287858B2 (en) 2006-08-10 2012-10-16 Jon Barron Proteolytic enzyme formulations
AT504159A1 (de) 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc Verwendung von proteasen
MX2009009967A (es) 2007-03-23 2009-10-07 Danisco Us Inc Genencor Div Produccion mejorada de amilasa por adicion n-terminal a proteina amilasa madura.
JP2008290966A (ja) 2007-05-24 2008-12-04 Michiharu Sasaki 養毛剤
RU2527894C2 (ru) 2007-11-27 2014-09-10 Альгифарма ИПР АС Использование альгинатных олигомеров в борьбе с биопленками
AT506095A1 (de) * 2007-12-03 2009-06-15 Volopharm Gmbh Verwendung von proteasen
US8309081B2 (en) 2008-11-18 2012-11-13 Scarguard Labs, Llc. Composition and method for treatment of bruising
JP2010126710A (ja) 2008-12-01 2010-06-10 Kao Corp バイオフィルム除去剤組成物
WO2010079209A2 (en) * 2009-01-08 2010-07-15 Golub Alexandr A Compositions for treating wounds and skin conditions
GB0905451D0 (en) 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
US9931381B2 (en) * 2009-11-23 2018-04-03 Prothera, Inc. Methods of comprising serratia peptidase for inhibition and treatment of biofilms related to certain conditions
CA2782622C (en) 2009-12-08 2018-05-22 Healthpoint, Ltd. Enzymatic wound debriding compositions with enhanced enzymatic activity
WO2012155027A1 (en) 2011-05-12 2012-11-15 Healthpoint, Ltd. Wound debridement compositions containing seaprose and methods of wound treatment using same
WO2013096337A1 (en) 2011-12-20 2013-06-27 Kci Licensing, Inc. Composition for enzymatic debridement
KR20150013280A (ko) 2012-05-11 2015-02-04 스미스 앤드 네퓨, 인크. 박테리아 균막을 제거하기 위한 세아프로제의 용도
CN109260465A (zh) 2012-11-14 2019-01-25 史密夫和内修公司 稳定的嗜热菌蛋白酶水凝胶
CN105050629B (zh) 2013-03-15 2018-09-25 史密夫和内修公司 用于递送活性剂的可溶解的形成凝胶的膜
CA2907175C (en) * 2013-03-15 2022-11-08 M. Alphabet 3, L.L.C. Methods and compositions for enhancing oxygen levels in tissues
JP6987039B2 (ja) 2015-08-24 2021-12-22 スミス アンド ネフュー インコーポレイテッド 抗菌剤と組み合わせた中極性油の細菌性バイオフィルムに対する相乗的抗菌活性

Similar Documents

Publication Publication Date Title
RU2014145270A (ru) Способ и композиция для разрушения бактериальной биопленки
Bigliardi et al. Povidone iodine in wound healing: A review of current concepts and practices
Konop et al. Certain aspects of silver and silver nanoparticles in wound care: a minireview
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
JP2016511310A5 (cg-RX-API-DMAC7.html)
ES2530417T3 (es) Dispositivo de apósito para su uso con una cánula o un catéter
JP2015504921A5 (cg-RX-API-DMAC7.html)
JP2012522037A5 (cg-RX-API-DMAC7.html)
CL2011002755A1 (es) Composicion farmaceutica topica que comprende particulas de fosfato de calcio nanoporosas, esfericas, donde al menos 90% o mas de las particulas tienen un diametro promedio de 2 micrometros o menos y estan enlazadas a un agente farmacologicamente activo.
JP2009519312A5 (cg-RX-API-DMAC7.html)
WO2015002932A8 (en) Antimicrobial compositions comprising hypochlorous acid and silver
JP2014505733A5 (cg-RX-API-DMAC7.html)
CN109700763A (zh) 用于治疗眼科病症的雄性激素组合物
WO2010079209A3 (en) Compositions for treating wounds and skin conditions
ECSP20010477A (es) Composición tópica semisólida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños crónicos de la piel
MX2015017629A (es) Combinaciones farmaceuticas.
US20260115372A1 (en) Wound care product
CN106070291A (zh) 一种抗菌组合物及其制备方法和应用
JP2012508256A5 (cg-RX-API-DMAC7.html)
JP2010533174A5 (cg-RX-API-DMAC7.html)
PE20211738A1 (es) Formulacion basada en ciclodextrina de un inhibidor de bcl-2
CL2009000065A1 (es) Proteina aislada que comprende una pluralidad de dominios rrl para utilizarse como agente anti-microbiano; composicion farmaceutica que comprende dicha proteina aislada; metodo para tratar infeccion microbiana.
WO2008117300A3 (en) Improved process for the preparation of cadexomer iodine
Sopata et al. Effect of Octenisept antiseptic on bioburden of neoplastic ulcers in patients with advanced cancer
Voljč et al. Contribution of topical agents to wound healing